TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)

NCT02920476 | Completed Phase 2 Results DMC FDA Drug

• 4 other identifiers: IRB201601359 -AUF-STO-LUNG-003IIT-USA-0113OCR15277
• Study Type: interventional
• Target: 4
• Locations: 1 country
• Sites: 1

Brief Summary

This is a non-randomized, open label, sequentially enrolling phase II study with a Simon two-step enrollment design to evaluate the activity of TAS-102 in previously treated unresectable or metastatic squamous non-small cell cancer after progression through or intolerance to prior systemic therapy. The trial therapy of TAS-102 is to be administered orally at 35 mg/m2 each dose twice daily. The primary objective of the trial is to determine the progression-free survival, in months, of subjects receiving TAS 102 for the treatment of unresectable or metastatic recurrent squamous non-small cell lung cancers.

Conditions

Squamous Cell Lung Carcinoma

Keywords

lung; metastatic; carcinoma

Outcome Measures

Primary Outcomes (1)

• Objective Response Rate (ORR)

  To determine the percentage of subjects who achieve an objective response by RECIST 1.1 criteria. ORR is defined as the number of participants who achieved either a partial or complete response by RECIST 1.1 criteria. By these criteria, Complete Response (CR) is defined as the disappearance of all target lesions and Partial Response (PR) is defined as a decrease of at least 30% in the sum of the longest diameter of the target lesions. Subjects must have received at least 2 cycles of therapy to be evaluable for this outcome measure.

  1 year

Secondary Outcomes (2)

• Clinical Benefit Rate

  1 year

• Overall Survival (OS)

  1095 days

Study Arms (1)

Treatment arm

EXPERIMENTAL

TAS-102

Drug: TAS-102

Interventions

TAS-102 DRUG

Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5. TAS-102 is to be taken within 1 hour of completion of morning and evening meals. Days 6 through 7: Rest Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12. Days 13 through 28: Rest

Also known as: Lonsurf

Treatment arm

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Those who will be eligible will be all patients with unresectable and/or metastatic squamous cell non-small cell lung cancer who have disease which has been previously treated with an Food \& Drug Administration (FDA)- or National Comprehensive Cancer Network (NCCN)-approved platinum doublet. Patients who have not received such therapy must have medical reasons for not receiving such therapy. Those who have a molecularly targetable genetic mutation in their tumor must have also received the appropriate specific therapy for that mutation. All will be appropriate candidates for chemotherapy treatment.
• Subjects must meet all of the additional following criteria to be eligible for study participation:
• Eastern Cooperative Oncology Group (ECOG) Performance Status \<2
• Life expectancy \> 12 weeks
• Male or female' age \>18 years
• Patients of childbearing potential must be using an effective means of contraception.
• Histologic diagnosis of squamous non-small cell lung cancer that has been treated adequately in the metastatic or unresectable setting with a platinum doublet chemotherapy regimen and now has evidence of disease progression. Patients may have also received additional chemotherapy, such as an immune checkpoint inhibitor or no more than one additional cytotoxic agent (thus participants may have received between one to three prior lines of therapy for metastatic or unresectable disease).
• Patients who have received platinum-based doublet therapy in the neoadjuvant or adjuvant setting will only be eligible if they have experienced disease progression after their last dose of cytotoxic chemotherapy.
• Patients who have a neoplasm for which there currently exists an FDA-approved targeted therapy (such as to epidermal growth factor receptor \[EGFR\] activating mutations, or ALK or ROS1 gene rearrangements) must have received all such targeted therapies and either exhibited progressive disease through such treatments, or have been shown to be intolerant of such therapies, prior to enrollment on this study.
• Baseline laboratory values (bone marrow, renal, hepatic):
• Adequate bone marrow function:
• Absolute neutrophil count \>1000/µL
• Platelet count \>100'000/µL
• Renal function:
• Serum creatinine \< 2.0 mg/dL

You may not qualify if:

• Pregnant or lactating females
• Patients with a mixed histology NSCLC, such as adenosquamous carcinoma, where the squamous component is \<50% of the assessed lesion
• Patients with a mixed histology where there are any small cell elements
• Patients who have not received and progressed through, refused, or been intolerant of, a commonly utilized platinum-doublet therapy (cisplatin or carboplatin paired with docetaxel, paclitaxel, nab-paclitaxel, gemcitabine, vinorelbine, etoposide or irinotecan) administered for the treatment of unresectable or metastatic lung cancer.
• Patients who have not received the appropriate prior targeted therapy for their lung cancer if eligible
• Any invasive malignancy treated within 3 years prior to Cycle 1, Day 1
• Myocardial infarction or ischemia within the 6 months before Cycle 1' Day 1
• Uncontrolled' clinically significant dysrhythmia, or prolonged QT segment
• Uncontrolled malignant disease in the central nervous system (previously treated disease is eligible, provided it has been radiographically stable for at least four weeks)
• Radiotherapy within the 2 weeks before Cycle 1, Day 1. If any radiation has been administered to the target lesion there must be evidence of growth by radiographic assessments or physical examination
• Major surgery within the 2 weeks before Cycle 1, Day 1
• Any co morbid condition that' in the view of the attending physician' renders the patient at high risk from treatment complications
• Subjects unwilling to use an acceptable method to avoid pregnancy for the entire study period and for at least 24 weeks after the last dose of study drug.
• History of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.
• Prisoners or subjects who are involuntarily incarcerated.

Sponsors & Collaborators

• University of Florida: lead
• Taiho Oncology, Inc.: collaborator

Study Sites (1)

UF Health Cancer Center

Gainesville, Florida, 32608, United States

Location

MeSH Terms

Conditions

Neoplasm Metastasis; Carcinoma

Interventions

trifluridine tipiracil drug combination

Condition Hierarchy (Ancestors)

Neoplastic Processes; Neoplasms; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type

Results Point of Contact

• Title: Allison Allegra
• Organization: University of Florida

allisonallegra3@ufl.edu

352-294-5691

Study Officials

• Dennie Jones, MD

  University of Florida

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 27, 2016
• First Posted: September 30, 2016
• Study Start: July 19, 2017
• Primary Completion: December 3, 2018
• Study Completion: August 14, 2021
• Last Updated: June 23, 2022
• Results First Posted: December 17, 2019

Record last verified: 2022-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)